

REMARKS

Status

Upon entry of the amendments, Claims 17-22, 28, and 32-37 will be pending in this application. Support for the new claims 32-37 can be found in the in the discussion of the preparation of Formula IV in the original specification (see pages 17-18). No new matter will be added upon entry of this amendment.

Discussion


Applicants thank Examiner Anderson for her conversation with Applicants' consultant, David H. Vance, Ph.D., J.D., on April 19, 2005. During the conversation it was noted that Applicants would likely elect Claim 28 and amend Claims 17-22 to include the reaction that converted Formula IVa to Formula IV. The Examiner indicated that if Claim 28 were found to be allowable, then amended Claims 17-22 would likely be rejoined as they recite a process to make the compound of Claim 28. Applicants have elected Group II, Claim 28, and amended Claims 17-22 as discussed. Applicants have also included new Claims 32-37 that further recite reaction conditions for the formation of Formula IV. Rejoinder of Claims 17-22 (and new Claims 32-37) with elected Claim 28 is respectfully requested.

In view of the foregoing, Applicants submit that the application is now in condition for examination. Early notification of such action is earnestly solicited. If the Examiner has any questions or believes further discussion will aid examination and advance prosecution of the application, a telephone call to the undersigned is invited.

DOCKET NO.: PH-7115 DIV2
10/826,099

Respectfully submitted,

Date: April 26, 2005



Jing G. Sun, Ph.D.
Agent for Applicants
Registration No. 45,914.

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-3791 (phone)
(609) 252-4526 (fax)